Trial Information

Immunohistochemical Analysis of Human Transbronchial Biopsy Specimens Collected in a Phase I Chemoprevention Trial of Myo-Inositol in Heavy Smokers Conducted Outside the Intramural NCI Program

Human transbronchial biopsy specimens collected under protocol study numbers CDR0000302633;
BCCA-U98-0411; BCCA-C02-0298 will be immunohistochemically stained for activated Akt using
phospho-specific antibodies. These samples are part of a phase I chemoprevention trial of
myo-inositol being conducted in Vancouver, BC by the British Columbia Cancer Agency in
collaboration with the National Cancer Institute (NCI). The transbronchial specimens will
be sent to the NCI for analysis of activated AKT. The study aims to determine whether
myo-inositol, a putative inhibitor of the upstream kinase phosphatidylinositol 3-kinase, can
alter activated Akt levels in smokers with bronchial dysplasia.